Skip to content

The COPD Attack Study

Frequency and Predictors of Exacerbations Within a COPD Population in Uganda

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05779384
Acronym
COPA
Enrollment
323
Registered
2023-03-22
Start date
2019-07-07
Completion date
2021-03-30
Last updated
2023-03-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Exacerbation COPD, Pulmonary Disease, Chronic Obstructive

Brief summary

The goal of this observational study is to evaluate the frequency and predictors of exacerbations in COPD patient population in Uganda. The main questions it aims to answer are:- 1. What is the proportion of frequent exacerbators (≥2/year) and what factors are associated with the frequent exacerbator phenotype? 2. What is the frequency of exacerbations and what factors are correlated with exacerbation frequency? Participants will be asked to offer demographic ,clinical and exposure questions. Questionnaires assessing disease burden, and quality of life will be administered. Clinical measurements, and complete blood count will be collected ta baseline and on sick visits. Spirometry will be measured at baseline and on the last visit. Samples will be collected for storage. Participants will be followed up for one year.

Detailed description

In this prospective observational study aimed at evaluating the frequency and predictors of exacerbations in a COPD population, the following were the objectives. Primary objective 1\. To estimate the proportion and predictors of frequent COPD exacerbations in Ugandans with COPD. Secondary objective(s) 1. To determine the frequency and predictors of exacerbations among COPD patients in Uganda 2. To evaluate the aetiologies of COPD exacerbations including eosinophilia, and bacterial causes. 3. To evaluate outcomes such as quality of life, lung function decline in patients with exacerbations by frequency of the exacerbations. COPD will be diagnosed as follows Definitions and diagnostic criteria for COPD and its grading, and that of an exacerbation have been provided by the GOLD guidelines 4 . This study will use the GOLD definitions and classifications. As per GOLD 2018 guidelines 4 , COPD will be considered in any patient with appropriate spirometry who has dyspnea, chronic cough or sputum production, and/or a history of exposure to risk factors for the disease. GOLD 2018 definition of an exacerbation: An acute worsening in respiratory symptoms that results in additional therapy. A) Mild exacerbation: Requires additional treatment with short acting bronchodilators only B) Moderate exacerbation: Requires additional treatment with short acting bronchodilators plus antibiotics and / or oral corticosteroids C) Severe exacerbation: Requires hospitalization or visit to emergency room. participants will be followed up at three monthly intervals, except when they have had a severe exacerbation, where they will be followed up at two weekly intervals until they stabilise. During the follow up visit, participant's COPD diaries will be evaluated for exacerbation length, severity and frequency as well as health care utilization. Additionally the CAT, CCQ and MRC dyspnoea scale questionaires, to evaluate the impact of COPD on quality of life will be administered. Finally lung function will be evaluated by spirometry.

Interventions

OTHERIt was an observational study

data collected concerning the incidence of exacerbations

Sponsors

GlaxoSmithKline
CollaboratorINDUSTRY
University College, London
CollaboratorOTHER
Makerere University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
30 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

* Age ≥30yrs * COPD diagnosis as per protocol (page 7) * Attending URAC clinic sites * Written informed consent * Able to fill in diary or has attendant who can help fill it out * Willing to attend follow up visits as required by study

Exclusion criteria

* Active pulmonary tuberculosis * Other important co-morbid disease likely to affect participation or outcomes, such as lung cancer, asthma and any other that may be deemed so, in which case be discussed on case by case basis by the investigational team.

Design outcomes

Primary

MeasureTime frameDescription
Proportion and predictors of frequent exacerbators in a COPD patient population in Uganda1 year period of follow upThe proportion of participants who had more than 2 exacerbations in the period of follow up and factors associated with these

Secondary

MeasureTime frameDescription
Frequency and predictors of exacerbations (e.g infections, biomarkers) in this patient populationsone yearThe frequency of exacerbations that participants developed and the factors associated with these

Countries

Uganda

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026